GlassScriptPhysician profile
Luis A Lozano
NPI 1316318033
$25,116.70
in general payments reported to CMS, 2019-2025
16 companies · $4,895 in 2025
The $4,895 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $1,275 · 2023: $732 · 2024: $409 · 2025: $4,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,890 · Travel and Lodging: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,890.00 |
| Travel and Lodging | $1,694.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15,900.18 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $2,450.71 | 2025 | Inbrija |
| Biogen, INC. | $1,681.59 | 2025 | Skyclarys |
| Neurocrine Biosciences, INC. | $1,245.48 | 2021-2025 | Ingrezza, Ongentys |
| Boston Scientific Corporation | $947.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $576.66 | 2021-2023 | Austedo Xr, Austedo |
| Kyowa Kirin, INC. | $472.12 | 2021-2025 | Nourianz |
| Abbott Laboratories | $344.28 | 2021-2023 | Infinity |
| Mdd US Operations, LLC | $332.30 | 2021-2025 | Gocovri |
| Amneal Pharmaceuticals LLC | $242.97 | 2022-2025 | Crexont |
| Acadia Pharmaceuticals INC | $228.47 | 2021-2022 | |
| Avion Pharmaceuticals | $207.34 | 2022 | |
| Ptc Therapeutics, INC. | $154.69 | 2025 | |
| Acorda Therapeutics, INC | $127.46 | 2023-2024 | Inbrija |
| Abbvie INC. | $127.20 | 2024-2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $77.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Lozano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.